metastatic/adv melanoma (mML) | |
mML - L1 - all population | |
nivolumab followed by ipilimumab | CheckMate 064 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -